Phase II study of lonidamine in metastatic breast cancer.

por Pronzato, P., Amoroso, D., Bertelli, G., Conte, P. F., Cusimano, M. P., Ciottoli, G. B., Gulisano, M., Lionetto, R., Rosso, R.
Publicado 1989

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II...

por Tibaldi, C, Vasile, E, Antonuzzo, A, Di Marsico, R, Fabbri, A, Innocenti, F, Tartarelli, G, Amoroso, D, Andreuccetti, M, Dico, M Lo, Falcone, A
Publicado 2008

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

por Vasile, E, Masi, G, Fornaro, L, Cupini, S, Loupakis, F, Bursi, S, Petrini, I, Di Donato, S, Brunetti, I M, Ricci, S, Antonuzzo, A, Chiara, S, Amoroso, D, Andreuccetti, M, Falcone, A
Publicado 2009

PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of...

por Marmorino, F., Cremolini, C., Loupakis, F., Antoniotti, C., Barbara, C., Dargenio, F., Miraglio, E., Masi, G., Salvatore, L., Schirripa, M., Borelli, B., Marcucci, L., Antonuzzo, L., Chiara, S., Banzi, C., Amoroso, D., Bonetti, A., Martignetti, A., Paris, M., Boni, L., Tomcikova, D., Falcone, A.
Publicado en Ann Oncol (2016)